Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PARG | Q86W56 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PER2 | O15055 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5259729 | 0.81 | DHFR (0.46) | DHFRTSHRUSP2HPGDMAPK1 | |
| SCHEMBL6689039 | 0.78 | NPC1 (0.45) | DHFRALDH1A1TSHRNPSR1KDM4E | |
| SCHEMBL5260181 | 0.77 | NPC1 (0.50) | DHFRALDH1A1NPSR1KDM4E | |
| SCHEMBL6305077 | 0.77 | ALDH1A1 (0.59) | L3MBTL1ALDH1A1POLBTSHRUSP2 | |
| SCHEMBL6235260 | 0.76 | TSHR (0.63) | DHFRALDH1A1POLBTSHRMAPK1 | |
| SCHEMBL1716008 | 0.76 | CNR2 (0.48) | DHFR | |
| SCHEMBL5263281 | 0.74 | PGR (0.50) | ALDH1A1POLBTSHRUSP2HPGD | |
| SCHEMBL6737897 | 0.74 | CNR2 (0.46) | DHFRTSHRPARGKDM4EPER2 | |
| SCHEMBL8070199 | 0.73 | SMN1; SMN2 (0.53) | L3MBTL1ALDH1A1POLBTSHRUSP2 | |
| SCHEMBL5309142 | 0.72 | HPGD (0.44) | DHFRALDH1A1POLBTSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | RPL5, RPL7, RPL35 | DHFR 963/4885L3MBTL1 3952/4885ALDH1A1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.